{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Single+intravenous+doses+of+placebo&page=3", "query": { "intervention": "Single intravenous doses of placebo", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 676, "total_pages": 68, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Single+intravenous+doses+of+placebo&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Single+intravenous+doses+of+placebo&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-09T09:40:06.540Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05814016", "title": "A Study of Danavorexton in People With Obstructive Sleep Apnea After General Anesthesia for Abdominal Surgery", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Sleep Apnea" ], "interventions": [ { "name": "Danavorexton", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "30 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "30 Years to 75 Years" }, "enrollment_count": 41, "start_date": "2023-05-11", "completion_date": "2024-09-25", "has_results": false, "last_update_posted_date": "2025-09-16", "last_synced_at": "2026-10-09T09:40:06.540Z", "location_count": 19, "location_summary": "Sheffield, Alabama • Phoenix, Arizona • La Jolla, California + 14 more", "locations": [ { "city": "Sheffield", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "West Hollywood", "state": "California" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05814016" }, { "nct_id": "NCT01934361", "title": "Phase Ib/II Study of Buparlisib Plus Carboplatin or Lomustine in Patients With Recurrent Glioblastoma Multiforme", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent Glioblastoma Multiforme" ], "interventions": [ { "name": "buparlisib", "type": "DRUG" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "lomustine", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2014-02-28", "completion_date": "2016-07-07", "has_results": false, "last_update_posted_date": "2020-12-09", "last_synced_at": "2026-10-09T09:40:06.540Z", "location_count": 5, "location_summary": "Phoenix, Arizona • Fayetteville, Arkansas • Chicago, Illinois + 2 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01934361" }, { "nct_id": "NCT04737486", "title": "A First-in-Human Study of AV-001 in Healthy Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Covid19-associated ARDS", "Covid19", "ARDS" ], "interventions": [ { "name": "AV-001", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Vasomune Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 48, "start_date": "2020-12-16", "completion_date": "2021-03-10", "has_results": false, "last_update_posted_date": "2021-03-24", "last_synced_at": "2026-10-09T09:40:06.540Z", "location_count": 1, "location_summary": "Cincinnati, Ohio", "locations": [ { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT04737486" }, { "nct_id": "NCT06052059", "title": "A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Ulcerative Colitis" ], "interventions": [ { "name": "IV Tulisokibart", "type": "DRUG" }, { "name": "IV Placebo", "type": "DRUG" }, { "name": "SC Tulisokibart", "type": "DRUG" }, { "name": "SC Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "16 Years to 80 Years" }, "enrollment_count": 1109, "start_date": "2023-10-25", "completion_date": "2029-08-01", "has_results": false, "last_update_posted_date": "2026-09-28", "last_synced_at": "2026-10-09T09:40:06.540Z", "location_count": 76, "location_summary": "Dothan, Alabama • Fairhope, Alabama • Litchfield Park, Arizona + 65 more", "locations": [ { "city": "Dothan", "state": "Alabama" }, { "city": "Fairhope", "state": "Alabama" }, { "city": "Litchfield Park", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Sun City", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT06052059" }, { "nct_id": "NCT00349726", "title": "Single-Dose Intravenous Inositol Pharmacokinetics in Preterm Infants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Infant, Newborn", "Infant, Low Birth Weight", "Infant, Small for Gestational Age", "Infant, Premature", "Retinopathy of Prematurity", "Bronchopulmonary Dysplasia (BPD)" ], "interventions": [ { "name": "Inositol lower volume", "type": "DRUG" }, { "name": "Inositol higher volume", "type": "DRUG" }, { "name": "Placebo lower volume", "type": "DRUG" }, { "name": "Placebo higher volume", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "NICHD Neonatal Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Days", "maximum_age": "6 Days", "sex": "ALL", "summary": "3 Days to 6 Days" }, "enrollment_count": 74, "start_date": "2006-06", "completion_date": "2007-12", "has_results": false, "last_update_posted_date": "2017-06-20", "last_synced_at": "2026-10-09T09:40:06.540Z", "location_count": 11, "location_summary": "New Haven, Connecticut • Indianapolis, Indiana • Detroit, Michigan + 7 more", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Albuquerque", "state": "New Mexico" }, { "city": "Rochester", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00349726" }, { "nct_id": "NCT04471038", "title": "Safety, Tolerability, and Pharmacokinetics of SAB-176 in Healthy Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Influenza Type A", "Influenza Type B", "Influenza" ], "interventions": [ { "name": "SAB-176", "type": "BIOLOGICAL" }, { "name": "Normal Saline", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "SAb Biotherapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 27, "start_date": "2020-07-29", "completion_date": "2021-04-19", "has_results": true, "last_update_posted_date": "2025-01-06", "last_synced_at": "2026-10-09T09:40:06.540Z", "location_count": 1, "location_summary": "Austin, Texas", "locations": [ { "city": "Austin", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04471038" }, { "nct_id": "NCT01651351", "title": "GLASSIA Infusion Rate Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Alpha1-antitrypsin Deficiency", "Healthy Volunteers" ], "interventions": [ { "name": "Alpha1-proteinase inhibitor", "type": "BIOLOGICAL" }, { "name": "Placebo: Human albumin 2.5%", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Baxalta now part of Shire", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 30, "start_date": "2012-07-31", "completion_date": "2013-01-16", "has_results": true, "last_update_posted_date": "2021-05-25", "last_synced_at": "2026-10-09T09:40:06.540Z", "location_count": 1, "location_summary": "Overland Park, Kansas", "locations": [ { "city": "Overland Park", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01651351" }, { "nct_id": "NCT00556439", "title": "Abatacept for Treating Adults With Giant Cell Arteritis and Takayasu's Arteritis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Takayasu's Arteritis", "Giant Cell Arteritis" ], "interventions": [ { "name": "Abatacept", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "15 Years", "maximum_age": null, "sex": "ALL", "summary": "15 Years and older" }, "enrollment_count": 97, "start_date": "2008-12", "completion_date": "2015-08", "has_results": true, "last_update_posted_date": "2018-02-26", "last_synced_at": "2026-10-09T09:40:06.540Z", "location_count": 8, "location_summary": "Los Angeles, California • Baltimore, Maryland • Boston, Massachusetts + 5 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00556439" }, { "nct_id": "NCT01291602", "title": "A Study to Assess the Safety, Tolerability and Pharmacokinetics of NXL104 Alone and in Combination With Ceftazidime Administered as Single and Repeated Intravenous Doses in Healthy Japanese Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Male and Female Japanese Volunteers" ], "interventions": [ { "name": "NXL104", "type": "DRUG" }, { "name": "CAZ104", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "20 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "20 Years to 45 Years" }, "enrollment_count": 15, "start_date": "2011-02", "completion_date": "2011-04", "has_results": false, "last_update_posted_date": "2017-09-01", "last_synced_at": "2026-10-09T09:40:06.540Z", "location_count": 2, "location_summary": "Glendale, California • Baltimore, Maryland", "locations": [ { "city": "Glendale", "state": "California" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01291602" }, { "nct_id": "NCT00331175", "title": "Safety, Toleration and Pharmacokinetics of Single Intravenous Doses of Peptide YY in Overweight Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Obesity" ], "interventions": [ { "name": "Peptide YY3-36", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 31, "start_date": "2006-07", "completion_date": "2006-12", "has_results": false, "last_update_posted_date": "2006-12-15", "last_synced_at": "2026-10-09T09:40:06.540Z", "location_count": 1, "location_summary": "New Haven, Connecticut", "locations": [ { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT00331175" } ] }